Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06492941

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

A Randomized, Double-blind, Multicenter Phase Ⅲ Clinical Study of Docetaxel for Injection (Albumin Bound) Combined With Best Supportive Care Versus Placebo Plus Best Supportive Care in Advanced Pancreatic Cancer

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
142 (estimated)
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin Bound) in combination with best supportive care versus placebo in combination with best supportive care in participants with pancreatic cancer who have received gemcitabine-containing and fluorouracil-containing regimens.

Detailed description

This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin bound) plus best supportive care versus placebo plus best supportive care in participants with pancreatic cancer who have received a previous treatment regimen containing gemcitabine and fluorouracil. It is planned to enroll 142 participants, and participants will be randomized to receive Docetaxel for Injection (albumin bound) in combination with best supportive care or placebo in combination with best supportive care in a 2:1 ratio. Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Conditions

Interventions

TypeNameDescription
DRUGDocetaxel for Injection (Albumin bound)Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.
DRUGPlaceboPlacebo was human blood albumin without the active ingredient docetaxel
DRUGBest supportive careBest supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Timeline

Start date
2024-08-12
Primary completion
2026-04-14
Completion
2026-11-21
First posted
2024-07-09
Last updated
2024-07-09

Source: ClinicalTrials.gov record NCT06492941. Inclusion in this directory is not an endorsement.

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer (NCT06492941) · Clinical Trials Directory